Berenberg lowered the firm’s price target on AstraZeneca to 12,500 GBp from 13,300 GBp and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- Mixed Day for Vaccine Stocks as Terrible News Emerges
- AstraZeneca sBLA for Flumist Quadrivalent accepted for review by FDA
- AstraZeneca says FDA accepts sBLA for self-administration FluMist Quadrivalent
- AstraZeneca to hold a virtual meeting
- AstraZeneca: Enhertu demonstrated meaningful survival in Phase II trial